Table 2.
Comparison of the first two mRNA-based COVID-19 vaccine candidates.
| Developers | Vaccine | Vaccine platform | Coronavirus target | Type of Candidate Vaccine | Emergency use authorization | Dosage, schedule, and route of administration | Confirmed efficacy | Clinical trial registry number |
|---|---|---|---|---|---|---|---|---|
| Moderna/NIAID | mRNA-1273 | mRNA-based therapeutics | SARS-CoV-2 Spike protein | LNP-encapsulated nucleoside-modified mRNA | US (Dec 18, 2020), Canada (Dec 23, 2020), Israel (January 4, 2021), EMA (Jan 6, 2021) | Two intramuscular injections (100 μg per dose), 28 days apart | 94.1% (measured starting from 14 days after the second dose) | NCT04470427 |
| BioNTech/Pfizer | BNT162b2 | mRNA-based therapeutics | SARS-CoV-2 Spike protein | LNP-encapsulated nucleoside-modified mRNA | UK (Dec 2, 2020), Canada (Dec 9, 2020), US (Dec 11, 2020), EMA (Dic 21, 2021), other countriesa | Two intramuscular doses, 21 days apart (30 μg per dose) | 95% (measured starting from seven days after the second dose)b | NCT04368728 |
US, The United States; EMA, European Medicines Agency; UK, The United Kingdom
a
December 31, 2020 (Argentina, Ecuador, Chile, Panama, Mexico, Costa Rica, Kuwait, Singapure, Switzerland, South Arabia)
b
Differences in efficacy (between 94.5% and 95%) are small compared to the potential variables between the studies.